Compare · ABT vs TLPH
ABT vs TLPH
Side-by-side comparison of Abbott Laboratories (ABT) and Talphera Inc. (TLPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and TLPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 2550.1x TLPH ($68.8M).
- ABT has been more active in the news (12 items in the past 4 weeks vs 8 for TLPH).
- ABT has more recent analyst coverage (25 ratings vs 2 for TLPH).
- Company
- Abbott Laboratories
- Talphera Inc.
- Price
- -
- -
- Market cap
- $175.37B
- $68.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2011
- News (4w)
- 12
- 8
- Recent ratings
- 25
- 2
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest TLPH
- Director Wan Mark A was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)
- Director Todisco Joseph was granted 5,100 shares, increasing direct ownership by 80% to 11,497 units (SEC Form 4)
- Director Jain Abhinav was granted 5,100 shares, increasing direct ownership by 70% to 12,412 units (SEC Form 4)
- Director Hoffman Stephen J was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)
- Director Broadfoot Jill Marie was granted 5,100 shares, increasing direct ownership by 60% to 13,647 units (SEC Form 4)
- Director Bozilenko Marina was granted 5,100 shares, increasing direct ownership by 56% to 14,147 units (SEC Form 4)
- Director Adams Adrian was granted 5,100 shares, increasing direct ownership by 29% to 22,709 units (SEC Form 4)
- Talphera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- H.C. Wainwright resumed coverage on Talphera with a new price target
- Chief Medical Officer Aslam Shakil covered exercise/tax liability with 4,518 shares, decreasing direct ownership by 6% to 76,542 units (SEC Form 4) to cover taxes